[
  {
    "ts": null,
    "headline": "eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience",
    "summary": "eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations.",
    "url": "https://finnhub.io/api/news?id=6594dac239c130537f7fb42fb49ac7ae0eb2dfda6363bbcc32785de686522a7d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761234900,
      "headline": "eschbach's Shiftconnector® Helps Power Merck's Visual Factory to Drive Greater Transparency, Agility, and Supply Chain Resilience",
      "id": 137197966,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "eschbach is pleased to share that Merck (NYSE: MRK), known as MSD outside the United States and Canada, has selected Shiftconnector to improve how it uses digital tools in manufacturing. By integrating Shiftconnector into its established visual factory framework, Merck is enhancing its ability to deliver real-time, actionable insights across global operations.",
      "url": "https://finnhub.io/api/news?id=6594dac239c130537f7fb42fb49ac7ae0eb2dfda6363bbcc32785de686522a7d"
    }
  },
  {
    "ts": null,
    "headline": "Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
    "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=bf3c5a059b63befba3d34be24337d3a9ad91f9d4707bc23b538162221b0ca3d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761228032,
      "headline": "Merck (MRK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release",
      "id": 137197967,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=bf3c5a059b63befba3d34be24337d3a9ad91f9d4707bc23b538162221b0ca3d5"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”",
    "summary": "Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently highlighted. Discussing the post-earnings rally of the stock, Cramer remarked: “Then there’s Danaher, DHR, the life sciences and diagnostic equipment company, which has been a huge disappointment for my Charitable Trust for so long. Not today, though. Today, Danaher gave us the quarter we’ve […]",
    "url": "https://finnhub.io/api/news?id=b32af9e7b076c371877a3f8c778933a4aa30621ed308a5232da4452c1edbc269",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761225636,
      "headline": "Jim Cramer Says “Danaher Gave Us the Quarter We’ve Been Looking For”",
      "id": 137197968,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Danaher Corporation (NYSE:DHR) is one of the stocks Jim Cramer recently highlighted. Discussing the post-earnings rally of the stock, Cramer remarked: “Then there’s Danaher, DHR, the life sciences and diagnostic equipment company, which has been a huge disappointment for my Charitable Trust for so long. Not today, though. Today, Danaher gave us the quarter we’ve […]",
      "url": "https://finnhub.io/api/news?id=b32af9e7b076c371877a3f8c778933a4aa30621ed308a5232da4452c1edbc269"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025",
    "summary": "RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to advancing research across hypercholesterolemia and pulmonary arterial hypertension (PAH) to help address the global burd",
    "url": "https://finnhub.io/api/news?id=d22db7dcdb81f4f791667389d8326b0168f8879427b60e14f72cbfee513922bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761216300,
      "headline": "Merck to Present New Data from Its Innovative Cardio-Pulmonary Pipeline and Portfolio at AHA Scientific Sessions 2025",
      "id": 137197969,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present new research from the company’s cardio-pulmonary portfolio and pipeline at the American Heart Association (AHA) Scientific Sessions 2025 in New Orleans, La., from November 7–10. Data presented at AHA highlight Merck’s continued dedication to advancing research across hypercholesterolemia and pulmonary arterial hypertension (PAH) to help address the global burd",
      "url": "https://finnhub.io/api/news?id=d22db7dcdb81f4f791667389d8326b0168f8879427b60e14f72cbfee513922bf"
    }
  },
  {
    "ts": null,
    "headline": "Nanobiotix S.A: Behind The Recent Momentum",
    "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
    "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761215085,
      "headline": "Nanobiotix S.A: Behind The Recent Momentum",
      "id": 137196767,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1281832252/image_1281832252.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Despite potential blockbuster royalties, NBTX's $1.1B stock valuation appears stretched due to limited pipeline and reliance on J&J for development. Read the full analysis here.",
      "url": "https://finnhub.io/api/news?id=0127b2e224e3f5a2e06d17c9ba056b5729805fc2de7402af0ef893528c008f4b"
    }
  },
  {
    "ts": null,
    "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
    "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
    "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761213917,
      "headline": "Viking Therapeutics: The Prime Target In The Obesity Gold Rush",
      "id": 137196743,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2241752128/image_2241752128.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Viking Therapeutics focuses on metabolic therapies with a strong pipeline, takeover potential, and late-stage obesity drug VK2735. Check out why VKTX stock is a buy.",
      "url": "https://finnhub.io/api/news?id=b9a82a43323d724bd37247a20ed5cf0728ad753ea2ec3a15956818d98315b03a"
    }
  },
  {
    "ts": null,
    "headline": "FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer",
    "summary": "RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev® (enfortumab vedotin-ejfv), for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are inel",
    "url": "https://finnhub.io/api/news?id=426b86d2350f85e64e6fc6309ccdafd147466f6d2694d25bde7fe152a0ec317b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761213600,
      "headline": "FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each in Combination with Padcev® (enfortumab vedotin-ejfv), for Certain Patients with Muscle-Invasive Bladder Cancer",
      "id": 137197970,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., October 23, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for two supplemental Biologics License Applications (sBLA) for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Padcev® (enfortumab vedotin-ejfv), for the treatment of patients with muscle-invasive bladder cancer (MIBC) who are inel",
      "url": "https://finnhub.io/api/news?id=426b86d2350f85e64e6fc6309ccdafd147466f6d2694d25bde7fe152a0ec317b"
    }
  }
]